Asheville, North Carolina – March 17, 2015 Avadim Technologies Inc. (“Theraworx®”) announced today that Peter M. Elias, MD, has agreed to join Avadim’s Medical & Science Advisory Board.
Chairman and CEO, Stephen Woody said, “Dr. Elias brings a lifetime of published work on the stratum corneum, the outer layer of the skin, and its critical role in protecting us against disease and infection, to our medical & science advisory board. We are pleased to have his world-renowned expertise in our corner, as we identify the optimal ways our customers can use Theraworx to control infection rates in their facilities.”
Dr. Peter Elias stated that, “It is my pleasure to join the Theraworx Medical & Science Board. I look forward to helping them achieve their primary goal of eliminating unnecessary infections, worldwide. I also look forward to studying how this unique product can help address other skin conditions which involve stratum corneum dysfunction.”
About Dr. Elias:
Peter M. Elias, M.D. is a Professor Emeritus in the Department of Dermatology at the University of California San Francisco, and a Staff Physician at the Veterans Affairs Medical Center, San Francisco. He received his medical degree from the University of California San Francisco and trained in dermatology at Harvard University. Dr. Elias has authored or co-authored over 600 peer-reviewed scientific articles and innumerable review articles; and he has edited or co-authored three books on the subject of the skin barrier in health and disease. He is an invited speaker at national and international scientific meetings; and has been a consultant to the pharmaceutical and cosmetic industries.
Dr. Elias was elected to memberships in the American Society for Clinical Investigation and the American Association of Professors. He is the recipient of many honors, including the William Montagna and the Kligman-Frost Awards from the Society of Investigative Dermatology.
Dr. Elias has devoted his research program to elucidating multiple aspects of epidermal biology, focusing primarily on the skin’s permeability barrier, as well as its other protective functions. All of his research ultimately is aimed at improving the care of dermatology patients through a better understanding of disease-causing mechanisms and through the development of novel therapies, with improved safety profiles, aimed at counteracting pathological processes.
About Theraworx®:
Avadim’s patented Theraworx products and patent-pending protocols have demonstrated a proven ability to help hospitals control hospital-acquired conditions. The unique Theraworx formula helps preserve the body’s natural skin function, by preventing dry skin and helping to maintain the natural acidic, anti-microbial nature of the skin’s outermost layer.
For more information on Theraworx™, visit www.theraworx.com.
Partnera critical path to get products on the s
About Avadim Technologies, Inc. & Theraworx®:
Avadim Technologies, Inc. was formed in 2007, with a simple vision of improving patient care. Our desire is to transform standard health care practices with our safe and effective Theraworx™ Technology, with the ultimate goal of fighting unnecessary infections on a global level. The name Avadim means “to serve”, providing opportunity for global outreach and giving back through the Eblen Center for Social Enterprise’s program Beyond All Borders. To learn more about Avadim Technologies, Inc., visit https://hcp.theraworxprotect.com and follow @theraworx.
Press Contact:
Mandy Allfrey
The Buzz, LLC
828.450.4840
Company Contact:
Joe McGuire
Chief Financial Officer
Avadim Technologies Inc.
877.677.2723
[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]